

---

# Index

- Alpha Therapeutics, 21
- AIDS, 10-17, 37, 44, 99-107
  - directed donations, 17
  - evaluation of donor screening criteria, 14
  - identification of suspected AIDS-carrying donors, 16
  - laboratory tests for AIDS, 16
- alternatives and substitutes for blood products, 20
  - impact on consumers, 22
  - impact on the plasma derivatives industry, 21
  - impact on the voluntary whole blood sector, 22
- alternative technologies, 133-172
  - alternative sources of blood products, 133-151
    - platelet substitutes, 150
      - liposomes as platelets, 151
    - red blood cell substitutes, 136
    - stem cell culturing, 134
      - hemoglobin solutions, 141
    - liposomes, **146**
    - perfluorochemicals, 138
  - alternative source for plasma products—use of recombinant DNA technology, 152-172
  - application of recombinant DNA technology to large-scale production of plasma-proteins, 159
- American Association of Blood Banks, 4, 9, 23, 35, 52, 54, 112
- American Blood Commission (ABC), 3, 9, 24, 34, 55, 108
- American Blood Resources Association (ABRA), 6
- American Council on Transplantation, 187
- American Red Cross (ARC), 4, 8, 9, 19, 23, 24, 35, 52, 53, 60, 61, 65, 114
- appropriate use of blood products, 22
  - direct attempts to improve use, 23
  - indirect effects on improved use, 23
- blood and blood products, 36-38
  - risks for donors, 39
- blood services complex, 4, 51-75
  - commercial plasma and plasma derivatives sector, 63-73
    - sources of raw plasma, 65
  - finished products licensed for use in the United States, **67**
    - coagulation factors, 69
    - costs of major plasma derivatives, 72
    - immune globulins, 70
    - normal serum albumin and plasma protein fraction, 67
    - reagent products, 72
  - voluntary, whole blood, and blood components sector, **51-62**
    - blood collecting organizations, 52
    - blood collections in the voluntary sector, 57
    - costs of blood and blood components, 59
    - costs and charges for blood products, 59
- blood technologies, 79-95
  - plasma fractionation technologies, 91
    - fractionation methods and products, 93
    - new and emerging technologies, 95
  - plasma collection, **91**
  - technologies for blood collection and processing, 79-91
    - blood collection, **80**
    - blood component preparation, 84
    - pre-transfusion testing techniques, **90**
    - testing and labeling of blood from doctors, **85**
- containment of health care costs, 18
  - DRG method of payment, 19
  - financing of blood center operations, 19
  - supply and distribution systems, **20**
- coordination of blood resources, **23**
  - American Blood Commission, 24
  - regionalization, 24
  - sharing and the blood credit system, 24
- costs of blood products, 7, 17
- Council of Community Blood Centers (CCBC), 4, 52, 54
- current issues, 99-129
  - appropriate use of blood products, 121-129
    - albumin and plasma protein fraction, 126
    - cryoprecipitate, 125
    - Factor VIII, 127
    - fresh-frozen and single-donor plasma, 126
    - granulocytes, 125
    - methods to change usage patterns, 127
    - platelets, 124
    - red cell concentrates, 122
    - whole blood, 121
  - coordination of blood resources, 107-117
    - American Association of Blood Banks, 112
    - American Red Cross, 114
    - regionalization, 108
    - resource sharing, 111
    - volume of sharing, 115
  - impact of AIDS on blood collection and use, 99-107
  - impact of health care cost containment, 117-121

Clearinghouse Lifeline Program, 111, 112, 113  
Congress:

House Committee on Energy and Commerce, 4

Canadian Red Cross, 25

Centers for Disease Control (CDC), 13, 41, 100

Department of the Army, 44

Department of Health and Human Services

(DHHS), 3, 14, 15, 33, 43, 103

Department of Justice, 9, 111

diagnosis-related groups (DRGs), 118

Factor VIII, 64, 72, 92, 93, 95, 101, 126, 127, 164, 165

Factor IX Complex, 95, 101

Federal activities, 41-48

Food and Drug Administration (FDA), 45-47

National Institutes of Health (NIH), 43

payment for blood products and services, 42

Health Care Financing Administration, 42

payment for hemophilia care, 43

Food and Drug Administration (FDA), 5, 10, 12, 13, 15, 33, 34, 41, 45, 100, 103

future directions, 175-188

organ and tissue banking, 181

American Council on Transportation, 187

compatibility, 186

current scene, 182

procurement system, 183

supply and demand, 184

voluntary v. commercial approaches, 175-181

prospects for further voluntary sector

involvement in plasma operations, 179

voluntary efforts in the plasma sector, 176

Genentech, 20

General Accounting Office (GAO), 35, 36, 59

Genetics Institute, 20

Green Cross of Japan, 21

Gulf Coast Regional Blood Center, **62, 107**

Hastings Center, 16

Health Care Financing Administration (HCFA), 36, 41, 42, 59, 120

history of Federal interest, 33-36

Irwin Memorial Blood Bank, 14, 104

issues, 12

League of Red Cross Societies, 40

legislation:

National Heart Act, 43

National Heart, Blood Vessel, Lung, and Blood Act of 1972, 43

Public Health Service Act of 1975 (Public Law 9443), 34, 43

Senate Bill, S. 140, 35

Senate Bill, S. 1610, 35

Social Security Amendments of 1983, 41

Massachusetts Biologics Laboratory, 9

Mississippi Blood Services (MBS), 62

National Blood Policy (NBP), 3, 12, 33

National Cancer Institute, 43

National Gay Task Force, 13, 100

National Heart, Lung, and Blood Institute, 16, 33, 34, 36, 43, 44

National Hemophilia Foundation, 13, 101

National Institutes of Health (NIH), 13, 41, 43, 100

Netherlands Red Cross, **38**

**New York Blood Center, 5, 6, 9, 14, 52, 65, 109**

**Nixon, President Richard M., 33**

**Puget Sound Blood Center, 23**

**Rite-Aid Corp., 5**

**safety, 10**

Stanford Medical Center, 11

Stanford University Blood Bank, 14

Titmuss, Prof. Richard, 33

Truman, President Harry S., **33**

voluntary v. commercial blood sources, 25

**World Health Organization (WHO), 40, 175**